Summit Partners Public Asset Management’s Oruka Therapeutics ORKA Stock Holding History

Summit Partners Public Asset Management’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$62.7M	Buy	+658,301	New	+$43.9M	1.1%	22

Other funds holding ORKA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Summit Partners Public Asset Management's ORKA Position: Q2 2026 in Review

Summit Partners Public Asset Management opened a new position in Oruka Therapeutics (ORKA) in Q2 2026: 658,301 shares worth $62.7M. The stake represents 1.1% of the portfolio and ranks #22 among its holdings.

255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

Summit Partners Public Asset Management held 658,301 shares of Oruka Therapeutics worth $62.7M as of Q2 2026.
Oruka Therapeutics was a new Summit Partners Public Asset Management position in Q2 2026.
Oruka Therapeutics made up 1.1% of Summit Partners Public Asset Management's portfolio in Q2 2026, its #22 holding.
255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Summit Partners Public Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.